Answers are grounded in this paper and cite their sources.
Tumor cells remodel their membrane lipids, and the extracellular vesicles (EVs) they release carry the result: EV lipid profiles differ from those of the parent cells because certain membrane components are selectively enriched. Headgroup chemistry, acyl-chain composition and cholesterol set how tightly a membrane packs and how easily it bends, and local anionic lipids recruit trafficking proteins. Two routes link these properties to exosome biogenesis: ARF6–PLD2–syntenin–ALIX, and ceramide production by neutral sphingomyelinase 2. Once vesicles are released, their surface lipids affect clearance and immune recognition. Phosphatidylserine promotes macrophage uptake and can suppress T cells, and vesicle-bound autotaxin delivers lysophosphatidic acid to receptors on recipient cells. In tumors these activities have been linked to angiogenesis and immune suppression, and in some settings to antitumor immunity. We review how lipid classes act in these processes, keeping changes in vesicle production apart from changes in cargo and signaling, and we outline the measurements needed to tie a lipid perturbation to an EV-mediated tumor phenotype. Therapeutic options that follow from this work include targeting phosphatidylserine-dependent recognition and lipid-mediated immune activation. EV lipid profiles are being explored as biomarkers, but their clinical value depends on the biofluid, the separation method and the intended diagnostic use.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: